Evolve Private Wealth LLC Purchases New Holdings in Elanco Animal Health Incorporated $ELAN

Evolve Private Wealth LLC acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 28,789 shares of the company’s stock, valued at approximately $708,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. NewEdge Advisors LLC increased its stake in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Elanco Animal Health in the 2nd quarter worth approximately $38,000. Root Financial Partners LLC boosted its position in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. purchased a new stake in shares of Elanco Animal Health in the 4th quarter worth approximately $41,000. Finally, Torren Management LLC purchased a new stake in shares of Elanco Animal Health in the 4th quarter worth approximately $46,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 1.8%

NYSE:ELAN opened at $24.41 on Tuesday. The company’s 50 day moving average price is $24.56 and its 200-day moving average price is $24.00. Elanco Animal Health Incorporated has a 52 week low of $17.11 and a 52 week high of $27.98. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The stock has a market cap of $12.20 billion, a price-to-earnings ratio of -59.54, a PEG ratio of 1.44 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter last year, the firm earned $0.26 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ELAN. JPMorgan Chase & Co. lifted their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Morgan Stanley increased their target price on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. Citigroup raised their price target on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. KeyCorp raised their price target on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.09.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Michael J. Harrington bought 5,000 shares of Elanco Animal Health stock in a transaction on Wednesday, August 12th. The stock was acquired at an average price of $21.82 per share, with a total value of $109,100.00. Following the acquisition, the director owned 131,451 shares in the company, valued at approximately $2,868,260.82. This trade represents a 3.95% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shiv O’neill purchased 3,998 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was acquired at an average price of $23.58 per share, with a total value of $94,272.84. Following the purchase, the insider directly owned 87,832 shares of the company’s stock, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 63,198 shares of company stock worth $1,473,109. Insiders own 1.14% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.